ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,375Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 16

$357K Total Retail Price of All Prescriptions

Rank: 13 out of 16

271 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
41% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Missouri
Lower avg

Schedule Two
Controlled Substances

26% of this provider’s 271 patients filled at least one prescription for a schedule two drug, compared to an average of 12%.

Schedule Three
Controlled Substances

21% of this provider’s 271 patients filled at least one prescription for a schedule three drug, compared to an average of 21%.

Risky Drugs to Seniors

2% of this provider’s 7,488 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$38 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

35 is the average number of prescriptions (including refills) per patient, compared to an average of 37.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Missouri
LISINOPRIL 433 364 1 4
LEVOTHYROXINE SODIUM 331 303 2 1
HYDROCODONE-ACETAMINOPHEN 321 238 S3 3 3
METFORMIN HCL 313 273 4 15
OMEPRAZOLE 299 225 5 8
SIMVASTATIN 269 227 6 5
METOPROLOL TARTRATE 249 237 7 10
WARFARIN SODIUM 248 226 8 9
LOVASTATIN 240 198 9 40
HYDROCHLOROTHIAZIDE 209 196 10 25
AMLODIPINE BESYLATE 191 173 11 7
FUROSEMIDE 185 185 12 2
SERTRALINE HCL 171 126 13 21
POTASSIUM CHLORIDE 157 157 14 6
MORPHINE SULFATE ER 155 56 S2 15 69
ATENOLOL 149 114 16 26
RANITIDINE HCL 139 123 17 17
TRIAMTERENE-HCTZ 134 102 18 92
ALLOPURINOL 133 101 19 50
GABAPENTIN 132 114 20 12
ATORVASTATIN CALCIUM 126 115 21 27
ALENDRONATE SODIUM 118 98 22 38
ZOLPIDEM TARTRATE 109 73 23 32
GEMFIBROZIL 103 55 24 172
OXYCODONE-ACETAMINOPHEN 98 54 S2 25 64
AMITRIPTYLINE HCL 96 63 R 26 112
ENDOCET 95 38 S2 27 176
DONEPEZIL HCL 93 82 28 11
CARVEDILOL 92 77 29 18
PRIMIDONE 88 88 30 146
NAMENDA 84 73 31 14
FLUTICASONE PROPIONATE 75 68 32 61
METOPROLOL SUCCINATE 71 44 33 24
TAMSULOSIN HCL 69 46 34 29
CYCLOBENZAPRINE HCL 68 13 R 35 98
CLOPIDOGREL 66 66 36 28
CITALOPRAM HBR 63 34 37 16
RAMIPRIL 60 60 38 158
FLUOXETINE HCL 56 30 39 63
LISINOPRIL-HYDROCHLOROTHIAZIDE 53 34 40 84
VERAPAMIL ER 52 51 41 173
TERAZOSIN HCL 51 48 42 164
GLIPIZIDE ER 51 29 42 127
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 17, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.